Omeprazole Teva Pharma

Omeprazole, the active ingredient in Omeprazole Teva Pharma, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children. GNH USA supplies Omeprazole Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Omeprazole Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑oesophageal reflux disease (GERD): Provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: Facilitates ulcer healing and reduces the risk of recurrence. - Zollinger‑Ellison syndrome: Controls excessive gastric acid production associated with gastrin‑secreting tumors. - Helicobacter pylori eradication regimens: Used as an adjunct to antibiotic therapy to improve eradication rates. - NSAID‑associated ulcer prevention: Lowers the risk of ulcer development in patients requiring chronic NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain or discomfort. - Flatulence: excess gas formation. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Clostridioides difficile‑associated colitis. - Acute interstitial nephritis. - Low magnesium levels (hypomagnesemia) with prolonged use. - Bone fractures with long‑term therapy. - Vitamin B12 deficiency with chronic use.

Omeprazole should be used with consideration of patient‑specific factors and proper storage.

- Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Use the lowest effective dose: limit duration to the shortest period necessary. - Monitor for signs of infection: especially Clostridioides difficile. - Evaluate bone health: consider calcium and vitamin D supplementation for long‑term users. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy. - Methotrexate (high‑dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requires more frequent monitoring. - Digoxin: may increase serum levels, watch for toxicity signs. - Phenytoin: possible reduction in serum concentration, monitor seizure control. - Diazepam: may increase plasma concentrations, observe for enhanced sedation.